Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2003

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions
Sarcoma
Interventions
DRUG

exatecan mesylate

Trial Locations (9)

10021

Memorial Sloan-Kettering Cancer Center, New York

32207

Nemours Children's Clinic, Jacksonville

38105

St. Jude Children's Research Hospital, Memphis

75230

Medical City Dallas Hospital, Dallas

80218

University of Colorado Cancer Center at University of Colorado Health Sciences Center, Denver

08903

Cancer Institute of New Jersey, New Brunswick

75390-9063

Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

M5G 1X8

Hospital for Sick Children, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT00055939 - Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma | Biotech Hunter | Biotech Hunter